IP Library Granted Patent US 8,664,247
Granted Patent B2
US 8,664,247 · App. 13/593,737 · Granted Mar 4, 2014

Acyclic organonitro compounds for use in treating cancer

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,664,247
App. No.
13/593,737
Granted
Mar 4, 2014
Kind
B2
Abstract

The present invention provides acyclic, geminal-dinitro organic compounds, methods of synthesizing the compounds, pharmaceutical compositions, therapeutic methods, and medical kits for treating various conditions using such compounds and pharmaceutical compositions. The compounds and compositions are useful in the treatment of cancer.

Claims (27)

1. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and at least one compound of Formula I:

or a pharmaceutically acceptable salt thereof, wherein:

R 1 is alkyl, cycloalkyl, or —(C 1 -C 4 )alkylene-N(R 7 )C(O)-haloalkyl;

R 2 , R 3 , and R 6 each represent independently for each occurrence hydrogen or alkyl;

R 4 is —X 2 —(C 1 -C 6 )alkylene-C(NO 2 ) 2 -alkyl; or R 4 is —N(R 6 )C(O)-haloalkyl when R 1 is —(C 1 -C 4 )alkylene-N(R 7 )C(O)-haloalkyl;

R 7 is alkyl;

X 2 is —O—(C 1 -C 4 )alkylene-O—;

n is 1, 2, or 3; and

the stereochemical configuration at any stereocenter in a compound represented by Formula I is R, S, or a mixture thereof.

2. The pharmaceutical composition of claim 1 , wherein R 1 is alkyl or cycloalkyl.

3. The pharmaceutical composition of claim 1 , wherein R 2 and R 3 are hydrogen.

4. The pharmaceutical composition of claim 2 , wherein R 4 is —X 2 —(C 1 -C 6 )alkylene-C(NO 2 ) 2 -alkyl.

5. The pharmaceutical composition of claim 1 , wherein n is 1.

6. The pharmaceutical composition of claim 1 , wherein the at least one compound is one of the following:

7. The pharmaceutical composition of claim 1 , wherein R 1 is —(C 1 -C 4 )alkylene-N(R)C(O)-haloalkyl, and R 4 is —N(R 6 )C(O)-haloalkyl.

8. The pharmaceutical composition of claim 7 , wherein R 6 and R 7 are alkyl.

9. The pharmaceutical composition of claim 8 , wherein n is 2, and R 2 and R 3 are hydrogen.

10. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and at least one compound selected from the following:

11. A method of treating cancer in a patient, comprising administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition of claim 1 in order to treat the cancer, wherein the cancer is squamous cell carcinoma, prostate cancer, skin cancer, small cell lung cancer, non-small cell lung cancer, bladder cancer, or cervical cancer.

12. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and at least one compound of Formula I-C:

or a pharmaceutically acceptable salt thereof, wherein:

R 1 is —(C 1 -C 4 )alkylene-OH or —(C 1 -C 4 )alkylene-OC(O)R 5 ;

R 2 , R 3 , and R 6 each represent independently for each occurrence hydrogen or alkyl;

R 4 is —OH or —OC(O)R 5 ;

R 5 represents independently for each occurrence hydrogen, alkyl, cycloalkyl, or aryl;

n is 1, 2, or 3; and the stereochemical configuration at any stereocenter in a compound represented by Formula I-C is R, S, or a mixture thereof.

13. The pharmaceutical composition of claim 12 , wherein the compound is one of the following:

Assignments (11)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 8, 2021
From: NORTHROP GRUMMAN INNOVATION SYSTEMS LLC
To: NORTHROP GRUMMAN SYSTEMS CORPORATION
Reel/Frame 055256/0892 →
CHANGE OF NAME Recorded Feb 4, 2021
From: NORTHROP GRUMMAN INNOVATION SYSTEMS, INC.
To: NORTHROP GRUMMAN INNOVATION SYSTEMS LLC
Reel/Frame 055223/0425 →
CHANGE OF NAME Recorded Nov 1, 2018
From: ORBITAL ATK, INC.
To: NORTHROP GRUMMAN INNOVATION SYSTEMS, INC.
Reel/Frame 047400/0381 →
RELEASE OF SECURITY INTEREST Recorded Jun 6, 2018
From: BANK OF AMERICA, N.A.
To: ALLIANT TECHSYSTEMS INC.; ATK/PHYSICAL SCIENCES, INC.; ORBITAL SCIENCES CORPORATION; ORBITAL ATK, INC.
Reel/Frame 045998/0801 →
TERMINATION AND RELEASE OF SECURITY INTEREST IN PATENTS Recorded Jun 6, 2018
From: WELLS FARGO BANK, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT
To: ORBITAL ATK, INC.
Reel/Frame 046477/0874 →
SECURITY AGREEMENT Recorded Sep 30, 2015
From: ORBITAL ATK, INC.; ORBITAL SCIENCES CORPORATION
To: WELLS FARGO BANK, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT
Reel/Frame 036732/0170 →
CHANGE OF NAME Recorded Jun 26, 2015
From: RADIORX, INC.
To: EPICENTRX, INC.
Reel/Frame 036021/0570 →
CHANGE OF NAME Recorded May 22, 2015
From: ALLIANT TECHSYSTEMS INC.
To: ORBITAL ATK, INC.
Reel/Frame 035753/0373 →
SECURITY AGREEMENT Recorded Nov 26, 2013
From: ALLIANT TECHSYSTEMS INC.; CALIBER COMPANY; EAGLE INDUSTRIES UNLIMITED, INC.; FEDERAL CARTRIDGE COMPANY; SAVAGE ARMS, INC.; SAVAGE RANGE SYSTEMS, INC.; SAVAGE SPORTS CORPORATION
To: BANK OF AMERICA, N.A.
Reel/Frame 031731/0281 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 18, 2012
From: WARDLE, ROBERT; CANNIZZO, LOUIS; STRAESSLER, NICHOLAS A.
To: ALLIANT TECHSYSTEMS INC.
Reel/Frame 029489/0848 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 14, 2012
From: SCICINSKI, JAN; ORONSKY, BRYAN T.
To: RADIORX, INC.
Reel/Frame 029471/0677 →